Aventis Loses Second Lovenox Patent Reissuance Bid

Law360, New York (July 27, 2004, 12:00 AM EDT) -- French drug maker Aventis SA has vowed to continue fighting for a reissuance of a patent for its best-selling anti-blood clotting drug Lovenox, even though its application was rejected twice by the U.S. Patent & Trademark Office.

Aventis said Tuesday it received a second rejection from the USPTO on its application for reissuance of U.S. patent no. 5,389,618 ('618 patent), which covers Lovenox.

Aventis filed an application with the USPTO to try to reissue the ‘618 patent in May 2003. Reissuance applications are typically used to...
To view the full article, register now.